These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23384679

  • 21. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma.
    Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Schaberg A, Kellerman DJ.
    J Asthma; 1996; 33(4):265-74. PubMed ID: 8707781
    [Abstract] [Full Text] [Related]

  • 22. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators.
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [Abstract] [Full Text] [Related]

  • 23. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW.
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [Abstract] [Full Text] [Related]

  • 26. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Galant SP, van Bavel J, Finn A, Gross G, Pleskow W, Brown A, Hamedani AG, Harding SM.
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
    [Abstract] [Full Text] [Related]

  • 27. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
    Siddall H, Quint D, Pandya H, Powley W, Shabbir S, Hohlfeld JM, Singh D, Lee L.
    PLoS One; 2020 Mar; 15(11):e0240964. PubMed ID: 33166307
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate.
    Fairfax A, Hall I, Spelman R.
    Ann Allergy Asthma Immunol; 2001 May; 86(5):575-82. PubMed ID: 11379810
    [Abstract] [Full Text] [Related]

  • 29. [Inhaled corticotherapy sparing effect by sodium nedocromil in moderate to severe asthma].
    Murciano D, Braunstein G, Montagut A, Pariente R.
    Rev Mal Respir; 1994 May; 11(5):485-92. PubMed ID: 7816992
    [Abstract] [Full Text] [Related]

  • 30. Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study.
    Leaker BR, Singh D, Lindgren S, Almqvist G, Eriksson L, Young B, O'Connor B.
    Respir Res; 2019 Dec 19; 20(1):288. PubMed ID: 31856838
    [Abstract] [Full Text] [Related]

  • 31. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
    Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.
    N Engl J Med; 2015 May 21; 372(21):1987-95. PubMed ID: 25981191
    [Abstract] [Full Text] [Related]

  • 32. A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.
    Psallidas I, Backer V, Kuna P, Palmér R, Necander S, Aurell M, Korsback K, Taib Z, Hashemi M, Gustafson P, Asimus S, Delaney S, Pardali K, Jiang F, Almquist J, Jackson S, Coffman RL, Keeling D, Sethi T.
    Am J Respir Crit Care Med; 2021 Feb 01; 203(3):296-306. PubMed ID: 32809843
    [Abstract] [Full Text] [Related]

  • 33. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
    Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M.
    Lancet; 2007 Oct 20; 370(9596):1422-31. PubMed ID: 17950857
    [Abstract] [Full Text] [Related]

  • 34. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma.
    Kupczyk M, Haque S, Middelveld RJ, Dahlén B, Dahlén SE, BIOAIR Investigators.
    Respir Med; 2013 Oct 20; 107(10):1521-30. PubMed ID: 23993706
    [Abstract] [Full Text] [Related]

  • 35. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
    Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, Parker D, Payton M, Collins LP, Pettipher R, Steiner J, Perkins CM.
    Clin Exp Allergy; 2012 Jan 20; 42(1):38-48. PubMed ID: 21762224
    [Abstract] [Full Text] [Related]

  • 36. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
    Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.
    J Allergy Clin Immunol; 2013 Sep 20; 132(3):567-574.e12. PubMed ID: 23726041
    [Abstract] [Full Text] [Related]

  • 37. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma.
    Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J.
    Eur Respir J; 2002 Nov 20; 20(5):1088-94. PubMed ID: 12449159
    [Abstract] [Full Text] [Related]

  • 38. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, Luskin AT, Solari PG.
    J Allergy Clin Immunol; 2017 Jul 20; 140(1):162-169.e2. PubMed ID: 27826098
    [Abstract] [Full Text] [Related]

  • 39. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.
    Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG.
    Respir Res; 2016 Mar 18; 17():29. PubMed ID: 26993628
    [Abstract] [Full Text] [Related]

  • 40. Dupilumab in persistent asthma with elevated eosinophil levels.
    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G.
    N Engl J Med; 2013 Jun 27; 368(26):2455-66. PubMed ID: 23688323
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.